Frequency and significance of anemia in non-Hodgkin's lymphoma patients

Annals of Oncology

Volumn 9, Issue 10, 1998, Pages 1109-1115

  Moullet, I ^a,b   Salles, G ^a,b   Ketterer, N ^a,b   Dumontet, C ^a,b   Bouafia, F ^a,b   Neidhart Berard, E M ^a,b   Thieblemont, C ^a,b   Felman, P ^a   Coiffier, B ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Anemia; Lymphoma; Prognostic factor

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CANCER CLASSIFICATION; CANCER INCIDENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031741680     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008498705032     Document Type: Article

References (41)

1. Douglas SW, Adamson JW. The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 1975; 45: 55-65.
2. Zarrabi MH, Lysik R, Di Stefano J et al. The anemia of chronic disorders: Studies of iron reutilization in the anemia of experimental malignancy and chronic inflammation. Br J Haematol 1977; 35: 647-52.
3. Dainiak N, Kulkarni V, Howard D et al. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983; 51: 1101-6.
4. Johannsen H, Jelkmann W, Wiedemann G et al. Erythropoietin/ hemoglobin relationship in leukemia and ulcerative colitis. Eur J Haematol 1989; 43: 201-6.
5. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-92.
6. Zucker S. Anemia in cancer. Cancer Invest 1985; 3: 249-60.
7. Jelkmann W, Page H, Wolff M et al. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50: 301-8.
8. Faquin WC, Schneider TJ, Goldberg MA et al. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94.
9. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by γ-interferon. J Cell Physiol 1992; 150: 59-64.
10. Mamus SW, Beck-Schroeder S, Zanzani ED. Suppression of normal human erythropoiesis by γ-interferon in vitro. J Clin Invest 1985; 75: 1496-503.
11. Johnson RA, Waddelow TA, Caro J et al. Chronic exposure to tumour necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130-8.
12. Means RT, Krantz SB. Progress in understanding of the anemia of chronic disease. Blood 1992; 80: 1639-47.
13. Rusten LS, Jacobsen SEW. Tumour necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: Role of p55 and p75 TNF receptors. Blood 1995; 85: 989-96.
14. Romaguera JE, McLaughin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 1991; 9: 762-9.
15. Leonard RCF, Hayward RL, Prescott RJ et al. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann Oncol 1991; 2: 655-61
16. Morel P, Lepage E, Brice P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: A report on 80 patients. J Clin Oncol 1992; 7: 1078-85.
17. Binet JL, Leporrier M, Dighiero G et al. A clinical staging system for chronic lymphoid leukemia: Prognostic significance. Cancer 1977; 40: 855-64.
18. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features and response to treatment and survival. Cancer 1975; 36: 842-54.
19. Straus DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173-86.
20. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
21. Shipp MA, Harrington DP, Anderson JR et al. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
22. Oken MM, Creech RH, Torney DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
23. Harris NL, Affe ES, Stein H et al. A Revised European American Classification of Lymphoid Neoplasm: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
24. Kaplan ES, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 452-81.
25. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 36: 187-220.
26. Bloomfield CD, Mc Kenna RW, Brunning RD. Significance of hematological parameters in the non-Hodgkin's malignant lymphomas. Br J Haematol 1976; 32: 41-6.
27. Cabanillas F, Smith T, Bodey GP et al. Nodular malignant lymphomas. Factors affecting complete response rate and survival. Cancer 1979; 44: 1983-9.
28. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470-80.
29. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-26.
30. Cowan RA, Jones M, Harris M et al. Prognostic factors in high-and intermediate-grade non-Hodgkin's lymphoma. Br J Cancer 1989; 59: 276-82.
31. Dixon DO, Neilan B, Jones SE et al. Effect on age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The South-west Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
32. Kaplan WD, Jochelson MS, Herman TS et al. Gallium-67 imaging: A predictor of residual tumour viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 1966-70.
33. Kwak LW, Halpern J, Olshen RA et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-77.
34. Ben-Ezra J, Burke JS, Schwartz WG et al. Small-lymphocytic lymphoma: A clinicopathologic analysis of 268 cases. Blood 1989; 73: 579-87.
35. Coiffier B, Bryon PA, French M et al. Intensive chemotherapy in aggressive lymphomas: Updated results of LHN-80. Protocol and prognostic factors affecting response and survival. Blood 1987; 70: 1394-9.
36. Conlan MG, Armitage JO, Bast M et al. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67: 1389-95.
37. Stein RS, Ultmann JE, Byrne GE et al. Bone marrow involvement in non-Hodgkin's lymphoma. Implications for staging and therapy. Cancer 1976; 37: 629-36.
38. Salles G, Bienvenu J, Barbier Y et al. Elevated levels of α-TNF and p55-R-TNF in lymphoma patients and their prognostic significance. Br J Haematol 1996; 93: 352-9.
39. Maksymiuk AW, Bratvold JS, Ezzat W et al. Non-Hodgkin's lymphoma in Saskatchewan: A review of 10 years' experience. Cancer 1994; 73: 711-9.
40. Stewart WP, Crowther D Mc William LJ et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma: A randomised prospective study with an assessment of prognostic factors. Cancer 1988; 61: 441-7.
41. Bartl R, Frisch B, Burkhardt R et al. Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): Correlation with clinical factors for diagnosis, prognosis. classification and staging. Br J Haematol 1982; 51: 511-30.